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Objectives This study investigated whether cardiac computed tomography angiography (CTA) can predict all-cause mortality
in symptomatic patients.
Background Noninvasive coronary angiography is being increasingly performed by CTA to assess for obstructive coronary ar-
tery disease (CAD), and minimal outcome data exist for coronary CTA. We have utilized a cohort of symptomatic
patients who underwent electron beam tomography to allow for longer follow-up (up to 12 years) than currently
available with newer 64-slice multidetector-row computed tomography studies.
Methods In all, 2,538 consecutive patients who underwent CTA by electron beam tomography (age 59  14 years, 70%
males) without known CAD were studied. Computed tomographic angiography results were categorized as signif-
icant CAD (50% luminal narrowing), mild CAD (50% stenosis), and normal coronary arteries. Multivariable
Cox proportional hazards models were developed to predict all-cause mortality. Risk-adjusted models incorpo-
rated traditional risk factors for coronary disease and coronary artery calcification (CAC).
Results During a mean follow-up of 78  12 months, the death rate was 3.4% (86 deaths). The CTA-diagnosed CAD was
an independent predictor of mortality in a multivariable model adjusted for age, gender, cardiac risk factors, and
CAC (p  0.0001). The addition of CAC to CTA-diagnosed CAD increased the concordance index significantly
(0.69 for risk factors, 0.83 for the CTA-diagnosed CAD, and 0.89 for the addition of CAC to CAD, p  0.0001).
Risk-adjusted hazard ratios for CTA-diagnosed CAD were 1.7-, 1.8-, 2.3-, and 2.6-fold for 3-vessel nonobstructive,
1-vessel obstructive, 2-vessel obstructive, and 3-vessel obstructive CAD, respectively (p  0.0001), when com-
pared with the group who did not have CAD.
Conclusions The primary results of our study reveal that the burden of angiographic disease detected by CTA provides both
independent and incremental value in predicting all-cause mortality in symptomatic patients independent of
age, gender, conventional risk factors, and CAC. (J Am Coll Cardiol 2008;52:1335–43) © 2008 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.07.027w
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dardiovascular disease remains the leading cause of death in
he U.S. (1). Current guidelines recommend that primary care
hysicians appropriately screen, identify, and implement vari-
us treatment interventions in patients at intermediate and
igh risk for coronary heart disease (CHD). Standard CHD
isk factor assessment in combination with traditional nonin-
asive stress imaging modalities, and more recently, coronary
rtery calcium score (CACS), are able to predict those patients
rom the Division of Cardiology, Department of Medicine, Los Angeles Biomedical
esearch Institute at Harbor-UCLA Medical Center, Torrance, California. Dr.
udoff is on the Speakers’ Bureau for General Electric. This study complies with
urrent ethical considerations and was approved by the Institutional Review Board.t
Manuscript received March 3, 2008; revised manuscript received July 11, 2008,
ccepted July 14, 2008.ho are at risk for coronary atherosclerosis. Invasive coronary
ngiography remains the gold standard for detection of ana-
omic coronary disease. Coronary computed tomography an-
iography (CTA) is an emerging technology that has the
otential to become a powerful tool in the gamut of noninva-
ive modalities to identify and prognosticate those patients
ith coronary artery disease (CAD).
See page 1344
Cardiac computed tomography is a robust technology for
he noninvasive assessment of a spectrum of cardiovascular
isease processes. Considerable advances have been made in
he field of cardiac imaging, particularly in the ability to
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with sufficient diagnostic accu-
racy (2). Traditionally, noninva-
sive coronary angiography has
been an arduous process given
the rapid cardiac motion, small
size of the vessels, tortuous ana-
tomical patterns, concomitant
calcification, and overlying veins.
These challenges require imag-
ing modalities used for noninva-
sive coronary angiography to
possess both high temporal and
spatial resolution. Cardiac com-
puted tomography has developed
rapidly and is now poised to be-
come a noninvasive method to
evaluate the lumen of the coro-
nary arteries. Original CTA
studies were performed with
electron beam tomography
(EBT) (3). This current study
utilized a cohort of symptomatic
atients who underwent EBT to allow for longer follow-up
up to 12 years) than currently available with newer 64-slice
ultidetector-row computed tomography (MDCT) studies.
omputed tomographic angiography, with both EBT and
DCT, has excellent negative predictive value and is an
nvaluable tool in evaluating symptomatic patients with an
ntermediate likelihood of CAD. The ability to visualize
oronary plaque (using both noncontrast and contrast com-
uted tomography [CT]) is promising, but fraught with
ome limitations (i.e., limited reproducibility, inability to
istinguish between fibrous and lipid laden plaque). Despite
ery high negative predictive values for both obstructive
isease and short-term cardiac events, use of CTA in
symptomatic patients as a screening test is currently not
ecommended because of its requirements for both signifi-
ant radiation and contrast administration. The purpose of
his study was to evaluate the incremental prognostic value
f atherosclerotic burden and degree of stenotic disease on
TA as well as of CAC over traditional risk factors in
redicting all-cause mortality in an outpatient setting with
ong-term follow-up.
ethods
atient population. This study sample included 2,538
onsecutive patients, 1,774 men and 764 women with an
verage age of 59 years (range 36 to 89 years), who were
hysician referred for evaluation of suspected CAD. Pa-
ients were excluded if found to have an irregular heart rate,
llergy to contrast medium, or impaired renal function.
atients referred for CTA evaluation with known prior
AD, including prior myocardial infarction, coronary artery
Abbreviations
and Acronyms
AUC  area under the
curve
CAC  coronary artery
calcification
CACS  coronary artery
calcium score
CAD  coronary artery
disease
CHD  coronary heart
disease
CI  confidence interval
CTA  computed
tomography angiography
EBT  electron beam
tomography
HR  hazard ratio
MDCT  multidetector-row
computed tomography
ROC  receiver-operator
characteristicisease on prior catheterization, or prior revascularization, (ere also excluded. After receiving a full explanation about
he procedure, all eligible patients provided signed written
nformed consent before the CTA.
Subjects were given a risk-factor questionnaire to assess
thnicity and cardiovascular risk factors. The presence and
umber of risk factors were calculated on the basis of the
ational Cholesterol Education Program guidelines (4).
isk factors included age (men 45 years, women 55
ears), current cigarette smoking, diabetes mellitus, history
f premature coronary disease in a first-degree relative (men
ge 55 years, women age 65 years), hypertension, and
ypercholesterolemia. In addition, body mass index data
ere collected.
TA protocol. The studies were performed with a C300
BT Scanner (GE-Imatron, South San Francisco, Califor-
ia). A noncontrast scan acquiring 35 slices was initially
erformed craniocaudally (3-mm section thickness without
ap) to obtain CACS. After this, a flow study was per-
ormed (8-mm section thickness with 4-mm intersection
ap) to obtain the circulation time (the time from the
ontrast injection in the vein to the peak visualization of the
scending aorta). The circulation time (average of 19 s in
his study) was determined by a time-density curve at the
ortic root, using 15 to 20 ml nonionic contrast injection
Iopamidol 370, Bracco Diagnostics, Plainsboro, New Jer-
ey). To facilitate adequate breath hold, the patients were
onnected to an oxygen mask and asked to hyperventilate
efore breath hold during scanning. Atropine was used to
ncrease heart rates when heart rates were 55 beats/min,
nd nitroglycerine (0.4 mg sublingual) was used in all
tudies unless contraindicated.
All CTA images utilized a 100-ms acquisition per image
nd were reconstructed with 512  512 matrix, 18-cm field
f view, yielding a voxel size of 0.34  0.34  3.0 mm3.
onionic contrast was administered through an antecubital
ein with an injection rate of 4 ml/s and total volume of 120
o 160 ml. Image acquisition was triggered to the patient’s
lectrocardiogram. Electrocardiogram-triggering corre-
ponding to a fixed point after the R-wave (rate-adjusted
rigger) to approximate end systole was done (5). The delay
ime after the R-wave was varied on the basis of the
esting heart rate just before the scan, previously demon-
trated to improve both calcium reproducibility and
iagnostic accuracy of CTA (6–8). The trigger delay was
50 ms for heart rates 60 beats/min, 320 ms for 61 to
0 beats/min, 300 ms for 71 to 80 beats/min, 280 ms for
1 to 90 beats/min, 260 ms for 91 to 100 beats/min, and
46 ms for heart rates 100 beats/min. The data
btained by the scanner for the analysis were transferred
nd processed at a dedicated, commercially available
mage workstation (Insight, Neo Imagery Technology,
ndustry, California).
TA study interpretation and reporting. All studies were
nalyzed by an experienced reader, blinded to all clinical
ariables, history, and patient demographics. Axial data
Fig. 1), as well as maximum intensity and volume-rendered
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October 14, 2008:1335–43 Mortality Rates After CTAubsets were used for analysis (Fig. 2). On the basis of the
TA results, the patients were assigned to 1 of the
ollowing groups: normal study (normal coronary arteries),
ild nonobstructive coronary artery disease (low-grade
therosclerosis of the coronary artery or arteries and lesions
50%), or significant obstructive coronary artery disease
lesions 50%). Because of the higher spatial resolution of
BT, no segments were deemed uninterpretable due to
otion. Dense calcifications were treated as nonobstructed
egments for the purpose of analysis. Within each of the
roups, the patients were further subdivided with respect to
he number of vessels diseased: 1-, 2-, or 3-vessel disease.
hree-vessel disease was defined as either obstructive CAD
n all 3 of the major epicardial vessels (right coronary, left
nterior descending, and left circumflex arteries) or right
oronary artery and left main artery disease.
ACS. Coronary artery calcium was defined as a plaque of
t least 3 contiguous pixels (area  1.03 mm2) with attenu-
tion of 130 HU or greater. The quantitative CACS was
Figure 2 Volume-Rendered CTA Image
A volume-rendered study demonstrating normal left anterior descending artery
(L), diagonal (D), and circumflex (C) branches. CTA  computed tomography
angiography.
Figure 1 Noninvasive Angiography
Noninvasive angiography shows axial slice (right) and volume-rendered images (le
demonstrates a high-grade stenosis of both the left anterior descending artery (whaalculated according to the Agatston method (9,10). The
otal CACS was calculated from the sum of each of the 4
ajor epicardial vessels (left main, left anterior descending,
ircumflex, and right coronary arteries).
nd points and definitions. Epidemiologic methods for
ollow-up included ascertainment of events blinded to
TA results. The primary end point was occurrence of
ll-cause mortality, which was verified by querying the
ocial Security Death Index. Death status was ascer-
ained in all patients (i.e., 100% follow-up). Patients who
nderwent cardiovascular scanning were followed up for a
ean of 6.5  1 years.
tatistical analysis. Analyses were performed with SPSS,
ersion 15 (SPSS Inc., Chicago, Illinois). All continuous
ata are presented as a mean value SD, and all categorical
ata are reported as a percentage or absolute number.
ruskal-Wallis tests and analysis of variance tests were used
o assess differences between groups. Kaplan-Meier survival
urves were constructed for CTA-diagnosed CAD and were
ompared with the log-rank test.
The effect of the CAD diagnosed by cardiac CT angiogra-
hy on all-cause mortality was determined using Cox regres-
ion analysis. After adjustment for age, gender, diabetes mel-
itus, hypertension, hypercholesterolemia, family history of
remature CHD, and coronary artery calcification, the forward
tepwise model was used to determine independent predictors
or all-cause mortality. Hazard ratios (HRs) and confidence
ntervals (CIs) were calculated. Receiver-operator characteristic
ROC) curves were constructed for 3 models: model I, a
omparative analysis of age and other cardiac risk factors;
odel II, CTA-diagnosed CAD; and model III, a combina-
ion of CTA-diagnosed CAD and CACS. Area under the
urve (AUC) was calculated to predict the ability of eachmodel
o detect all-cause mortality, with an AUC value of 0.50
ndicating no accuracy and a value of 1.00 indicating maximal
e volume-rendered image
row) and the right coronary artery (black arrow).ft). Th
ite arccuracy.
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linical characteristics. Overall, the study population
onsisted of 2,538 patients; 70% were men and the mean
ge was 59  14 years (range 36 to 89 years). The
ajority of the patients were Caucasian (n  1,893,
5.4%); 10.2% (n  259) were African American; 9.5%
n  241) Asian; 3.3% (n  84) Hispanic; and 2.4% (n
61) other. Of the studied patients, 1,085 (43%) had no
TA evidence of disease, 1,060 (42%) had nonobstruc-
ive CAD (50% stenosis severity), and 393 (15%) had
bstructive CAD. Patients with increasing severity of
AD tended to be older, male, hypertensive, hypercho-
esterolemic, and have a family history of premature
HD (p  0.0001) and diabetes (p  0.001). The CACS
Figure 3 Event-Free Survival by CTA
Risk-adjusted event-free survival by computed tomography angiography (CTA)-diagn
the group with CTA-diagnosed nonobstructive CAD (right). Risk adjustment include
mellitus, smoking, family history of premature coronary heart disease (right), and
tality. In patients with CTA-diagnosed nonobstructive CAD, increasing CACS was as
ssociation of Cardiovascular Risk Factors and Severity of CAD Dia
Table 1 Association of Cardiovascular Risk Factors and Severit
Variable
No CAD
(n  1,085)
1-Vessel
Nonobstructive
(n  750)
2-Vessel
Nonobstructive
(n  238)
Age (yrs) 54 15 61 11 61 10
Gender (male) 61% (662) 73% (547) 77% (183)
Hypertension 35% (380) 44% (330) 47% (111)
Diabetes mellitus 11% (119) 14% (105) 13% (31)
Hypercholesterolemia 38% (412) 54% (405) 68% (162)
History of smoking 5% (54) 7% (52) 8% (19)
Family history of CHD 35% (380) 47% (325) 53% (126)
BMI (kg/m2) 28.1 2.3 32.4 2.5 27.9 3.4
CACS — 343 40 466 34
All-cause mortality 18 20 11
Survival rate 98.3% 97.3% 95.4%
MI  body mass index; CACS  coronary artery calcium score; CAD  coronary artery disease; Clso increased with severity of CTA-diagnosed CAD (p
0.0001) (Table 1).
urvival by absence or presence of CAD. In the 15-year
ollow-up period, 86 all-cause deaths were observed, with
n event rate of 3.4% (86 of 2,538). Overall survival was
8.3% and 95.3% among the cohort when grouped
ccording to the absence or presence of CAD, respec-
ively (p  0.0001) (Fig. 3). The unadjusted and adjusted
Rs for mortality are shown in Table 2. After adjustment
or age, gender, hypertension, diabetes mellitus, hyper-
holesterolemia, history of smoking, family history of
HD, and baseline CAC, the stepwise multivariable
odel showed that the presence of coronary atheroscle-
osis was an independent predictor of mortality and had
oronary artery disease (CAD) (left), and coronary artery calcium score (CACS) in
following variables: age, gender, hypertension, hypercholesterolemia, diabetes
(left). The presence of CTA-diagnosed CAD increased the risk of all-cause mor-
ed with decreased survival.
ed by CTA
CAD Diagnosed by CTA
CTA-Diagnosed CAD
3-Vessel
onobstructive
(n  72)
1-Vessel
Obstructive
(n  310)
2-Vessel
Obstructive
(n  68)
3-Vessel
Obstructive
(n  15) p Value
65 12 64 11 62 11 64 9 0.0001
78% (56) 81% (251) 82% (56) 87% (13) 0.0001
43% (31) 50% (155) 54% (37) 67% (10) 0.0001
13% (9) 19% (59) 26% (18) 17% (3) 0.001
46% (33) 60% (186) 56% (38) 58% (9) 0.0001
7% (5) 8% (25) 4% (3) 20% (3) 0.12
46% (33) 42% (130) 51% (35) 67% (10) 0.0001
27.6 3.4 28.4 3.2 28.6 2.5 29 3.1 0.9
738 70 590 35 748 78 1,030 97 0.0001
5 22 7 3 0.0001
93.1% 92.9% 89.7% 80% 0.0001
coronary heart disease; CTA  computed tomography angiography.osed c
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CACS
sociatgnos
y of
N
s
C
S
b
t
s
e
9
n
9
3
a
c
C
c
0
p
S
A
s
i
p
p
s
C
(
r
a
h
t
r
i
o
(
H
R mily hi
1339JACC Vol. 52, No. 16, 2008 Ostrom et al.
October 14, 2008:1335–43 Mortality Rates After CTAignificant incremental value over clinical risk factors and
AC (HR: 2.51, 95% CI: 1.47 to 4.25, p  0.0001).
urvival by severity of CAD. Patients with CAD detected
y CTA were further partitioned into subgroups of obstruc-
ive (50% stenosis by CTA) and nonobstructive (50%
tenosis by CTA) disease and quantified as to number of
picardial vessels involved. Survival rates were 97.3%,
5.4%, and 93.1% for patients with 1-, 2-, and 3-vessel
onobstructive CAD, respectively. Survival rates were
2.9%, 89.7%, and 80% for patients with 1-, 2-, and
-vessel obstructive CAD, respectively (Fig. 4). Unadjusted
nd adjusted HRs for mortality are shown in Table 2. The
lassification of CAD severity by 3-vessel nonobstructive
AD and 1-, 2-, and 3-vessel obstructive CAD had
orresponding HRs of 1.74, 1.82, 2.31, and 2.59 (p 
.0001), demonstrating the additional prognostic predictive
ower of severity of CAD.
azard Ratios of Death and 95% Confidence Interval (in Parenthese
Table 2 Hazard Ratios of Death and 95% Confidence Interval (i
Models Unadjusted Model
With CTA-diagnosed any CAD 2.98 (1.78–5.01), p 0.0001
Without CTA-diagnosed CAD 1.0 (Reference)
1-vessel nonobstructive disease 1.13 (0.56–2.28), p 0.73
2-vessel nonobstructive disease 1.19 (0.72–1.95), p 0.49
3-vessel nonobstructive disease 1.82 (1.37–2.40), p 0.0001
1-vessel obstructive disease 1.89 (1.51–2.38), p 0.0001
2-vessel obstructive disease 2.44 (1.96–3.03), p 0.0001
3-vessel obstructive disease 2.63 (2.01–3.39), p 0.0001
elative risk adjustment included age, gender, hypertension, hyperlipidemia, diabetes mellitus, fa
Abbreviations as in Table 1.
Figure 4 CTA Event-Free Survival
Risk-adjusted event-free survival by computed tomographic angiography (CTA)-diagn
eased coronary arteries. Risk adjustment included the following variables: age, ge
premature coronary heart disease, and coronary artery calcium score. All-cause mo
of diseased coronary arteries.urvival by CACS in patients with nonobstructive CAD.
mong the 1,060 patients with CTA-diagnosed nonob-
tructive CAD, coronary artery calcium was found to be an
ndependent predictor of all-cause mortality. Six percent of
atients had scores of zero with nonobstructive disease
resent on contrast-enhanced EBT. Patients with nonob-
tructive CAD were divided into 4 groups according to
ACS: 1 to 9 (n  121), 10 to 99 (n  212), 100 to 399
n  292), and 400 (n  326); the corresponding survival
ates were 99.2%, 99%, 96.9%, and 96.1% (Fig. 3). After
djustment for age, gender, hypertension, diabetes mellitus,
ypercholesterolemia, history of smoking, and family his-
ory of CHD, the stepwise multivariable model (Cox
egression) showed that a CACS 100 to 399 and400 were
ndependent predictors of mortality in patients with non-
bstructive CAD and had significant incremental value
HR: 5.1, 95% CI: 1.6 to 14.56, p  0.003; HR: 6.2, 95%
ccording to CAD Status
entheses) According to CAD Status
Risk Factors Adjusted Model
Risk Factors and CACS
Adjusted Model
2.69 (1.59–4.53), p 0.0001 2.51 (1.47–4.25), p 0.0001
1.0 (Reference) 1.0 (Reference)
1.03 (0.30–1.75), p 0.69 0.97 (0.47–1.94), p 0.94
1.02 (0.68–1.9), p 0.52 0.98 (0.58–1.66), p 0.96
1.77 (1.34–2.34), p 0.0001 1.74 (1.49–2.05), p 0.0001
1.87 (1.4–2.51), p 0.0001 1.82 (1.45–2.3), p 0.0001
2.37 (1.91–2.93), p 0.0001 2.31 (1.86–2.89), p 0.0001
2.61 (2–3.37), p 0.0001 2.59 (1.99–3.68), p 0.0001
story of premature coronary heart disease, and smoking.
coronary artery disease (CAD) stratified by severity of disease and number of dis-
ypercholesterolemia, diabetes mellitus, smoking, hypertension, family history of
increased significantly by increasing severity of CTA-diagnosed CAD and numbers) A
n Parosed
nder, h
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Mortality Rates After CTA October 14, 2008:1335–43I: 1.5 to 10.5, p  0.001, respectively) (Table 3). In
omparison, the patients with nonobstructive CAD and
ACS of 1 to 9 had a 99.2% survival rate, with only 1 event
mong 121 patients.
ncremental value of burden of CAD on CTA in pre-
icting survival. Receiver-operator characteristic curves
ere generated to determine the predictive value of tradi-
ional risk factor assessment, extent of CAD as determined
y CTA, and CACS in combination with CTA disease
urden with respect to mortality. The AUC was calculated
or each model (Fig. 5). In our cohort of patients, we found
hat the angiographically significant CAD characteristics as
etected by CTA (model II) more accurately predicted
azard Ratios of Death and 95% Confidencenterval (in Parentheses) Across Groups of Patientsith Increasing CACS Among Those WithTA-Diagno ed Nonobstructive CAD (n  1,060)
Table 3
Hazard Ratios of Death and 95% Confidence
Interval (in Parentheses) Across Groups of Patients
With Increasing CACS Among Those With
CTA-Diagnosed Nonobstructive CAD (n  1,060)
Models Unadjusted Model Risk Factors Adjusted RR
CACS 1–9 1.0 (Reference) 1.0 (Reference)
CACS 10–99 2.6 (0.17–17.84), p  0.46 1.7 (0.21–12.84), p  0.39
CACS 100–399 5.4 (1.8–15.4), p  0.002 5.1 (1.6–14.56), p  0.003
CACS 400 6.4 (1.6–12.3), p  0.001 6.2 (1.5–10.5), p  0.001
isk factors adjusted were age, gender, hypertension, hyperlipidemia, diabetes mellitus, family
istory of premature coronary heart disease, and smoking.
RR  relative risk; other abbreviations as in Table 1.
Figure 5 Receiver-Operator Characteristic Curves
Receiver-operator characteristic curves for 3 models created to assess the ability
patients. CACS  coronary artery calcium score; CAD  coronary artery disease; Cortality than did traditional risk factor assessment (model
[AUC 0.83, 95% CI: 0.77 to 0.88, p  0.0001 vs. AUC
.69, 95% CI: 0.61 to 0.77, p 0.0001]). When CACS was
ombined with significant CAD detected on CTA (model
II), the AUC demonstrated even greater predictive power
han presence of significant CAD alone (AUC 0.89, 95%
I: 0.86 to 0.93, p  0.0001).
iscussion
he primary results of our study reveal that the burden of
ngiographic disease detected by CTA positively correlates
ith the incidence of all-cause mortality among patients
ith suspected CAD referred for evaluation in an outpatient
etting. Furthermore, this is the first study to demonstrate
hat CTA is incremental to traditional risk factors plus
oronary calcium in predicting all-cause mortality. Given
he recent emergence of CTA as an evaluation tool for
AD, very few prognostic data exist. To our knowledge,
his cohort represents the largest and longest follow-up after
TA in such a population, and is one of few studies
emonstrating the prognostic value of this technology. The
nd point, all-cause mortality, with 86 events, provides this
nvestigation with significant statistical power to evaluate
he prognostic significance of CTA using EBT.
mbination of clinical variables to predict all-cause mortality among symptomatic
coronary heart disease; CTA  computed tomography angiography.of a co
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October 14, 2008:1335–43 Mortality Rates After CTAWe utilized EBT to allow for longer follow-up. Clearly,
mproved spatial resolution is available now with MDCT.
t the time of the EBT studies, adequate MDCT angiog-
aphy was not yet available because of lower rotation speeds
nd fewer detectors. One of the most important advances
or coronary imaging has been faster gantry rotation speed,
esulting in better temporal resolution and improved z-axis
patial resolution made possible by thin collimations with
xtensive volumetric acquisition (11). The new 64-slice
DCT scanners provide fast scan times, improved cardiac
ating options, and isotropic resolution (which provides
-dimensional information free of superimposed tissues or
nterference, resulting in uniform resolution throughout).
he 64-slice detectors yield a 3-dimensional data set: for
xample, near isotropic voxels of 0.35  0.35  0.5 mm3
hat could be rotated in any given plane without loss of
esolution (12).
Our results suggest that CTA is a noninvasive modality
hat incrementally predicts all-cause mortality over tradi-
ional risk factor assessment. Computed tomographic an-
iography is a noninvasive method able to accurately quan-
ify anatomic epicardial coronary disease and differs from
ther noninvasive methods that rely on functional measure-
ents and surrogates of CAD. In our study, we have shown
hat the presence and extent of coronary atherosclerosis as
etected by contrast-enhanced EBT adds incremental prog-
ostic value over traditional risk factor assessment and the
ACS alone. There is a clear difference with respect to
urvival among patients with normal CT angiograms and
hose with detected atherosclerosis. Among the patients
ith nonobstructive CAD by CTA, the CACS has further
redictive power as patients with CACS 100 had a
ignificantly lower survival rate than patients with CACS 1
o 9. Patients with nonobstructive CAD and CACS 1 to 9 had
survival rate of 99.2%, with only 1 event occurring in the
roup of 121 patients. Patients with a normal CTA and
ACS of 0 had a survival rate of 99.8%, with only 1 event
ccurring in the group of 403 patients. This event rate is
imilar to a recent analysis of 25,257 patients in which the
0-year adjusted survival rate was 99.4% for patients with a
alcium score of 0 (13). A normal CTA with a CACS of 0
onveyed an excellent prognosis in this study population.
In the patients with CTA-detected disease, survival is
ignificantly negatively correlated with burden of angio-
raphic obstructive CAD, as well as 3-vessel nonobstructive
AD. In the patients with 1- and 2-vessel nonobstructive
AD, there was a trend toward increased mortality; how-
ver, the p value did not meet significance. Patients with the
ighest degree of CAD, 3-vessel obstructive disease, had
he lowest survival rates (80%), and the survival rates
mproved as the severity of CAD decreased. The results
emain evident even when adjusting for risk factors and
ACS. We know from previous studies using conventional
nvasive coronary angiography that higher angiographic
isease burden conveys a worse prognosis. The 6-year
ollow-up of the medical treatment arm in the CASS sCoronary Artery Surgery Study) trial (7) demonstrated a
igher incidence of mortality associated with higher angio-
raphic burden of disease. At 6 years, the survival rates were
s follows: no obstructive disease, 92%; 1-vessel disease,
7%; 2-vessel disease, 74%; and 3-vessel disease, 56% (7).
lthough our results show a similar trend, the overall
urvival among our cohort is improved, likely reflecting the
yriad advancements in medical, interventional, and surgi-
al therapies for the treatment of CAD in the last 3 decades,
ncluding revascularization and other antiatherosclerotic
herapies.
In our last analysis, we demonstrate the incremental
ower of CTA for detection and prognostication of all-
ause mortality over traditional risk factor assessment alone.
hen combined with CACS, CTA becomes even more
obust in predicting all-cause mortality, with an AUC
f 0.89.
It must be stressed that this CTA study was performed
ith EBT, not the more current 64- to 320-slice detector
ystems available. It is more difficult to detect noncalcified,
onstenotic plaque by EBT compared with newer scanners,
nd it is possible that a lot of the plaque that is now seen in
4-slice MDCT was missed by EBT scans. However,
linical diagnostic results from EBT parallel those of
DCT scanners. Several papers have compared calcium
cores, demonstrating almost identical results (8,14). Out-
ome studies of calcium scores have yielded similar predic-
ion of events using both MDCT and EBT (15). Similarly,
e have published results on the diagnostic accuracy of CT
ngiography using EBT compared with angiography that
arallel closely the diagnostic results of MDCT and coro-
ary angiography (16,17). We have published intravascular
ltrasound comparison data comparing electron beam com-
uted tomography-detected plaque and intravascular ultra-
ound, and the results parallel those in papers using MDCT
ngiography (1). Overall accuracy for electron beam com-
uted tomography angiography to determine plaque mor-
hology was 92% (54 of 59), demonstrating excellent
etection of underlying plaque type (calcified vs. noncalci-
ed) (18). The higher spatial resolution of MDCT should
mprove the diagnostic accuracy and the visualization of
oncalcified (nonobstructive) disease.
It has been suggested that CTA may be helpful to rule
ut the presence of significant CAD and avoid invasive
oronary angiography in patients with a low to interme-
iate clinical likelihood of significant CAD. Multiple
tudies have demonstrated CTA accuracies over 90%,
ith negative predictive values of 96% and 98% for the
resence of obstructive CAD (19,20). Outcome data with
TA are just developing. Lesser et al. (21) evaluated the
ccuracy of CTA with 16-slice MDCT for determining
ignificant CAD and a 6-month prognosis and clinical
utcome in a “real world” clinical setting. The 6-month
ollow-up of the 834 patients originally not referred for
ardiac catheterization showed 2 patients (0.2%) who sub-
equently had significant CAD. There were no cardiovas-
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Mortality Rates After CTA October 14, 2008:1335–43ular deaths (21). Pundziute et al. (22) analyzed the prog-
ostic value of CTA in patients with known or suspected
AD. A total of 100 patients (73 men, age 59  12 years)
ho were referred for further cardiac evaluation based on
uspicion of significant CAD underwent additional CTA to
valuate the presence and severity of CAD. The first-year
vent rate was 0% for patients with normal coronary arteries
n CTA versus 30% for patients with any evidence of CAD
n CTA. However, Pundzuite et al. (22) assessed ”soft”
vents (mainly revascularizations that may have been
rompted by the CT results). This study and others suggest
hat a normal CTA provides an excellent prognosis. Min et
l. (23) studied the association of all-cause death with the
TA-defined extent and severity of CAD. In a single-
enter consecutive cohort of 1,127 patients ages 45 years
ith chest symptoms, stenosis by CTA was scored as
inimal (30%), mild (30% to 49%), moderate (50% to
9%), or severe (70%) for each coronary artery. In patients
ith chest pain, CTA identified increased risk for all-cause
eath. Importantly, in both the study by Min et al. (23) and
he present study, a negative CTA portends an extremely
ow risk for death.
Gilard et al. (24) studied 141 patients whose CTA were
onsidered normal. During the follow-up period (mean 14.7
onths), those patients experienced 0% mortality, a 3.5%
ate of subsequent invasive angiography, and a 0.7% rate of
yocardial infarction (24). The risks of subsequent death,
ew referral for invasive angiography, and coronary events
ompare favorably with risks after normal invasive angiog-
aphy, which were 0.4%, 4.3%, and 0.6%, respectively.
In our study, the majority of the deaths (54 of 86, 63%)
ccurred among the patients without obstructive CAD by
BT. Patients with minor or intermediate coronary nar-
owings had an intermediate event rate, higher than that of
atients with normal or near normal coronary vessels. Acute
oronary events frequently occur after acute or subacute
bstruction to coronary blood flow at a site of previously
onobstructive coronary atheroma. Multiple studies over
he last decade have demonstrated that the vast majority of
yocardial infarctions (60% to 83%) occur at the site of a
onobstructive plaque (25,26). Virmani et al. (27) pointed
ut that these sites are frequently characterized by plaque
ith a thin fibrous cap and necrotic core that do not usually
how severe narrowing but rather positive arterial remodel-
ng. In addition, our study further adds evidence to the fact
hat increasing plaque burden as denoted by higher CACS
s a significant risk factor for outcomes in these vulnerable
atients and should be considered an excellent risk stratifi-
ation marker in the absence of significant nonstenotic
AD.
tudy limitations. This study was a single-center, retro-
pective, observational analysis of a large cohort of patients
eferred for CTA. The majority of patients had cardiac risk
actors and, therefore, are not representative of the general bopulation. In addition, we had incomplete information
ith respect to risk factors and the various treatment
nterventions implemented, as this information was ob-
ained by survey.
Given the design of the study, we were unable to
etermine the cause of death, and only report on all-cause
ortality; thus, our model likely includes events unrelated to
therosclerotic disease. However, the bias resulting from
ause of death misclassification does not occur in this model,
nd for this age group, the prevalence of CHD death has
een reported to be approximately one-half of deaths from
ll causes (28). With our rates of coronary risk factors higher
han in the general population, we expect our rates of
ardiac death also to be accordingly higher than the general
opulation rate of one-half of all-cause mortality. Patients
ith active cancer, acquired immune deficiency, congestive
eart failure, or advanced lung disease were generally not
eferred for CTA evaluation and were excluded from this
tudy.
There could also exist a treatment bias, whereby
atients with higher CAD burdens are more likely to be
reated aggressively, improving outcomes. We have pre-
iously demonstrated that patients with higher calcium
urdens are more likely to be placed on a regimen of
tatin therapy and more likely to maintain statin therapy
improved adherence) over the subsequent 3 to 5 years
29). Thus, higher calcium scores (and presumably CTA
urdens) are confounded by improved antiatherosclerotic
herapies that would possibly lower cardiovascular mor-
ality. However, this confounder would weaken the
redictive value of cardiac CT.
We utilized a cutpoint of 50% luminal severity due to the
nexactness of measuring stenosis on CTA. Symptomatic
esions with 50% to 75% diameter stenosis are generally
onsidered significant, and stenotic lesions 70% often
esult in revascularization procedures when evidence of
iable, ischemic myocardium is present in that vascular
istribution. Patients with lesser degrees of coronary arterial
tenosis may be managed with medical therapies. We
tilized a lesser cutpoint (50% stenosis present by CTA)
o be more conservative, given the intertest variability
etween CTA and cardiac catheterization (8,14–16,30). A
TA cutpoint of 70% luminal irregularity would have led
o fewer patients classified as having significant CAD, and
hus likely to decreased sensitivity for detection of obstruc-
ive disease.
Given the early experience of our center with CTA, all
ata included in this study were obtained using contrast-
nhanced EBT with electrocardiographic triggering as op-
osed to newer MDCT scanner technology that is currently
vailable. The ability to discern mixed plaque and noncal-
ific plaque has been demonstrated to be superior using the
ewer technology (7), and better risk stratification may now
e obtainable.
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side from several small studies with short-term follow-up,
here is a paucity of outcome data for the emerging
echnology of CTA, a modality that is currently being
tilized with increasing frequency. These results offer fur-
her validation of CTA and its clinical role in CAD
valuation and help to fill the outcome data void that exists
or this promising technology. Our results show that CTA
emonstrating the presence of luminal obstruction or non-
bstructive, noncalcified plaque in contrast-enhanced EBT
oronary angiography is a powerful noninvasive modality
hat accurately predicts all-cause mortality as correlated with
everity of CAD, with incremental benefit over traditional
isk factor assessment and CACS. Moreover, CAC scoring,
erformed concurrently with CTA at our institution, pro-
ides further prognostic information about patients with
ormal CT angiograms, and also imparts additional predic-
ive power when combined with CTA for patients with
therosclerosis.
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